Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,126 active trials259 approved drugs3,742 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,710 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,169)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06960707 | Two Versus One Week Breast Radiotherapy (RT)(PRATO) | recruiting | Phase 3 | 400 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07416994 | Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer | recruiting | Phase 3 | 440 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jun 15, 2026 |
| clinicaltrials |
| NCT05950945 | Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer | recruiting | Phase 3 | 250 | Daiichi SankyoINDUSTRY | 10 | Jun 12, 2026 | clinicaltrials |
| NCT06763328 | Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy | recruiting | Phase 3 | 80 | City of Hope Medical CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05593458 | Transarterial Neoadjuvant Chemotherapy vs.Traditional Intravenous Chemotherapy For Locally Advanced Gastric Cancer With SOX+PD-1(TACTIC) | recruiting | Phase 3 | 190 | Zhejiang UniversityOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07383441 | Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer | recruiting | Phase 3 | 718 | SWOG Cancer Research NetworkNETWORK | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05561387 | Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment | recruiting | Phase 3 | 510 | SWOG Cancer Research NetworkNETWORK | 1 | Jun 10, 2026 | clinicaltrials |
| NCT02821013 | Duration of Anti-PD-1 Therapy in Metastatic Melanoma(STOP-GAP) | recruiting | Phase 3 | 614 | Canadian Cancer Trials GroupNETWORK | 2 | Jun 9, 2026 | clinicaltrials |
| NCT07188025 | ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer(REACT) | recruiting | Phase 3 | 103 | Erasmus Medical CenterOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT05904119 | Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study(LEGATO) | recruiting | Phase 3 | 411 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 11 | Jun 8, 2026 | clinicaltrials |
| NCT06783491 | Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer(FOXHIPECT4) | recruiting | Phase 3 | 1,083 | Maimónides Biomedical Research Institute of CórdobaOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07234162 | A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) | recruiting | Phase 3 | 218 | Dizal PharmaceuticalsINDUSTRY | 3 | Jun 8, 2026 | clinicaltrials |
| NCT07632118 | Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer Surgery | recruiting | Phase 3 | 288 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT05243797 | Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation(MajesTEC-4) | recruiting | Phase 3 | 1,594 | European Myeloma Network B.V.NETWORK | 25 | Jun 4, 2026 | clinicaltrials |
| NCT07168980 | Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents(B-NHL) | recruiting | Phase 2 / Phase 3 | 87 | Children's Cancer Group, ChinaNETWORK | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07518173 | A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer | recruiting | Phase 3 | 596 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07590024 | RAIRI Model-Guided Adjuvant Therapy in Nasopharyngeal Carcinoma(RAIRI-NPC) | recruiting | Phase 3 | 651 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06112990 | Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression(CREATINE-52) | recruiting | Phase 3 | 200 | University of UtahOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07139873 | A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) | recruiting | Phase 3 | 250 | Dizal PharmaceuticalsINDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT06825091 | Is Adaptive SBRT for Prostate vs Image-guided Radiotherapy a True Evolution (ASPIRE)(ASPIRE) | recruiting | Phase 3 | 320 | University Health Network, TorontoOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05271240 | Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM | recruiting | Phase 3 | 432 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06851663 | Trop2-targeted immunoPET Imaging of Solid Tumors | recruiting | Phase 2 / Phase 3 | 400 | RenJi HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07615751 | Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in Advanced HER2-Positive Breast Cancer | recruiting | Phase 3 | 502 | Fudan UniversityOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07472153 | PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer | recruiting | Phase 2 / Phase 3 | 120 | N.N. Alexandrov National Cancer CentreOTHER_GOV | 1 | May 28, 2026 | clinicaltrials |
| NCT07237256 | Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib(NoLEEta) | recruiting | Phase 3 | 3,902 | UNICANCEROTHER | 5 | May 26, 2026 | clinicaltrials |
| NCT06998940 | Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations | recruiting | Phase 3 | 94 | SWOG Cancer Research NetworkNETWORK | 1 | May 22, 2026 | clinicaltrials |
| NCT07138209 | A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 3 | 228 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT07349069 | A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer | recruiting | Phase 3 | 5,500 | Shandong Suncadia Medicine Co., Ltd.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT07427043 | Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)(ROPES) | recruiting | Phase 3 | 300 | Brigham and Women's HospitalOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07462143 | A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer | recruiting | Phase 2 / Phase 3 | 80 | RemeGen Co., Ltd.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT07594340 | HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven) | recruiting | Phase 3 | 300 | Binkui LiOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07264075 | Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN(ILLUMINE) | recruiting | Phase 3 | 780 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05884255 | An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors. | recruiting | Phase 3 | 220 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT06127654 | Ventilation Imaging to Improve the Quality of Life for Patients With Lung Cancer Treated With Radiation Therapy(VITaL) | recruiting | Phase 3 | 165 | University of SydneyOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07154706 | Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) | recruiting | Phase 3 | 180 | Nuvation Bio Inc.INDUSTRY | 3 | May 19, 2026 | clinicaltrials |
| NCT03851445 | Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer | recruiting | Phase 2 / Phase 3 | 10,000 | SWOG Cancer Research NetworkNETWORK | 1 | May 18, 2026 | clinicaltrials |
| NCT06431633 | Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.(ARIAN) | recruiting | Phase 3 | 129 | Fundación GECPOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT06757634 | Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) | recruiting | Phase 3 | 1,180 | Celcuity IncINDUSTRY | 22 | May 18, 2026 | clinicaltrials |
| NCT05255653 | Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features(RAINBO) | recruiting | Phase 2 / Phase 3 | 1,615 | Leiden University Medical CenterOTHER | 4 | May 15, 2026 | clinicaltrials |
| NCT06277050 | Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma | recruiting | Phase 3 | 264 | Jiangxi Provincial Cancer HospitalOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07357298 | Phase III Trial of Brain MRI Surveillance in Stage IV Breast Cancer | recruiting | Phase 3 | 156 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07580300 | Proton Versus Photon Therapy in Head and Neck Squamous Cell Carcinomas.(PRORADNOR-RCT) | recruiting | Phase 3 | 400 | Oslo University HospitalOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT06284317 | A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.(ADOPT-lung) | recruiting | Phase 3 | 290 | ETOP IBCSG Partners FoundationNETWORK | 10 | May 14, 2026 | clinicaltrials |
| NCT06417814 | A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(TROPION-Lung15) | recruiting | Phase 3 | 744 | AstraZenecaINDUSTRY | 27 | May 14, 2026 | clinicaltrials |
| NCT06486142 | EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study(ERIS) | recruiting | Phase 3 | 200 | Region SkaneOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07583888 | VABu Conditioning in Elderly AML HSCT | recruiting | Phase 2 / Phase 3 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06437977 | Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)(neoR-TORCH) | recruiting | Phase 3 | 478 | Shanghai Chest HospitalOTHER | 1 | May 13, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jun 15, 2026source: clinicaltrials